Sareum shares rocket after ProNAi Therapeutics licenses cancer drug
Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.
Company
LON:SAR
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.
239 stories · page 3 of 3
Shares in Sareum have rocketed over 150% after it announced its cancer drug candidate has been licensed to ProNAi Therapeutics.
The major share price risers and fallers in London at 9.45am
FTSE 100 stocks ended softer on Tuesday as sterling remained nestled near to post-Brexit lows for a second successive session
Telit is collaborating with Indian information tech specialist, Vortex Biosciences granted licences for cell electroporation and Forbidden Technologies signs with a sports content group.
Investments and investor services
Investors have subscribed for 16.5mln Acorn Minerals shares at 15p a pop, raising the company £2.48mln. Shares rose to 13.25p.
The firm received similar patents the USA and Europe in September last year.
Sareum Holdings plays down a recent report, Eurasia Mining agrees a refining contract and Minds + Machines is seeing exceptional growth.
British Gas has lost 399,000 customers ... perhaps they are still there, they just weren't in when the company called.
Shares in Sareum jumped nearly 20% yesterday as investors latched onto to an article published earlier this month
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Two trials are expected to open in collaboration with partner the CRT Pioneer Fund, at the Royal Marsden Hospital, Sutton on May 31 this year.
Dr Parker currently sits on the boards of Silence Therapeutics, Albucasis Limited and sp2 Consulting Limited
AstraZeneca has reportedly held talks with San Francisco-based Medivation
Archive
In contrast to FTSE100, UK small caps were higher at the close, with Vast Resources still the top London gainer...
Stocks on London's junior market are at least having a better time of it than the blue-chips
Sareum Holdings PLC shares shot up over 30% as the cancer drug specialist received the regulatory green light for clinical trials of its candidate CCT245737...
Major share price risers and fallers in London at 3.30pm
The proceeds will be used to advance the company drug development programme
Board room coups are in the offing at CPPGroup and Nyota Minerals.
Archive
Small caps really didn't move much on a day which saw explosive action from the ECB and some fiery responses in the global market.
The FTSE AIM 100 Index rose 3.04 points to 3272 by mid-afternoon
Main share price risers and fallers in London at 16.15pm
"We are swiftly moving towards our goal of becoming a clinical-stage development company," said CEO, Dr Tim Mitchell
Archive
A round-up of news from the Proactive Investors universe.
The application means a £200,000 success milestone payment from Cancer Research Technology to Sareum.
Investments and investor services
IInvestors continued to bask in the glow from Sunrise Resources
Shares in drug discovery group Sareum Holdings (LON:SAR) shot up as it updated on the clinical trial process for its lead cancer candidate.
Investments and investor services
There were a lot of boardroom changes made today in the small cap space
Drug discovery group Sareum Holdings (LON:SAR) says it's optimistic about next year with two planned in-human clinical trials for its lead cancer candidate expected to start in early 2016.
Investments and investor services
A mixed reaction to changes to the board compositions of some companies.
Below are the main news-driven share price movements at 4pm.
Investments and investor services
Below are some of the main news-driven share price changes at 12.00pm.